Edwards Larry Todd 4

What Happened

• Larry T. Edwards, Executive Vice President & Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), sold 2,052 shares on 2026-02-02 in an open-market transaction. The reported weighted-average sale price was $25.50, for total proceeds of approximately $52,323. The sale was to cover tax withholding tied to the vesting of RSUs granted January 12, 2024.

Key Details

• Transaction date: February 2, 2026; Form filed February 4, 2026 (timely filing).
• Price: weighted average $25.50; individual trade prices ranged $24.745 to $25.68. (Reporting person can provide per-trade breakdown on request.)
• Reason: Sale to satisfy tax withholding obligation related to vesting of restricted stock units (RSUs).
• Shares owned after transaction: Not specified in the provided filing.
• Additional note: Footnote indicates holdings include 724 shares purchased under the company's Employee Stock Purchase Plan on 2025-11-30.

Context

• This was a tax-withholding sale tied to RSU vesting (routine administrative sale), not an independent judgment to reduce or increase exposure to the stock. Such sales are common when shares vest and the employer or insider sells a portion to cover withholding taxes.